Pediatrix Medical reports Q3 adjusted EPS 67c, consensus 47c

Reports Q3 revenue $493M, consensus $476.44M. “Our operating results for the third quarter exceeded our expectations and were driven by a combination of reimbursement-related factors, including strong collection activity, higher patient acuity and slightly favorable payor mix, as well as operational consistency,” said Mark Ordan, Chief Executive Officer of Pediatrix Medical (MD) Group. “We now expect our full year 2025 Adjusted EBITDA will likely range between $270 million and $290 million. We are of course pleased with our results, and the strength it provides to Pediatrix and our stakeholders, but know that they come at a time of change and uncertainty in the healthcare environment.”